Pressure mounts on silicone breast implants:
This article was originally published in Clinica
Seven leading Congressmen have written to FDA Commissioner David Kessler urging him to comment on US and international studies of silicone implant safety and to reassure women. So far, he has refused. Commenting on the British health authoritys' statement discounting a link between silicone breast implants and connective tissue diseases, an FDA spokesman said: "We are encouraged by recent studies showing that the immune-disease problem is smaller than we believed .... But the studies are not definitive. Nothing has been said about [implant] breakage and migration (of silicone within the body)."
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.